Penam Biosciences Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 12-12-2024
- Paid Up Capital ₹ 10.00 Cr
as on 12-12-2024
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 50.39 Cr
as on 12-12-2024
- Revenue %
(FY 2024)
- Net Worth 411.81%
(FY 2024)
- Total Assets 112.06%
(FY 2024)
About Penam Biosciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 10.00 Cr.
The company currently has active open charges totaling ₹50.39 Cr.
The Key Managerial Personnel (KMP) at Penam Biosciences Private Limited India is Shashi Jajware as COMPANY SECRETARY. Asha Dhingra, Aniket Dhingra, and Priyanka Aneja serve as directors at the Company.
- CIN/LLPIN
U24304HR2020PTC084593
- Company No.
084593
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jan 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Yamuna Nagar, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Penam Biosciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shashi Jajware  | Company Secretary | 23-Jul-2024 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Asha Dhingra | Director | 07-Jan-2020 | Current |
| Aniket Dhingra | Director | 07-Jan-2020 | Current |
| Priyanka Aneja | Additional Director | 23-Dec-2023 | Current |
Financial Performance of Penam Biosciences.
Penam Biosciences Private Limited, for the financial year ended 2024, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 411.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Penam Biosciences?
In 2024, Penam Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Protech Remedies Private LimitedActive 1 year 6 months
Asha Dhingra and Aniket Dhingra are mutual person
- S K S Metals Private LimitedActive 15 years 3 months
Asha Dhingra and Aniket Dhingra are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Aug 2024 | ₹3.00 M | Open |
Others Creation Date: 21 Jul 2023 | ₹0.90 M | Open |
Others Creation Date: 27 Sep 2022 | ₹26.50 Cr | Open |
How Many Employees Work at Penam Biosciences?
Unlock and access historical data on people associated with Penam Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Penam Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Penam Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
